[ad_1]
After announcing that a possible vaccination of the São Paulo population against the coronavirus could begin this year, the administration of João Doria (PSDB) withdrew today and adopted a more cautious tone, saying that it is not yet possible to specify when the doses will be available.
“The prospects are optimistic, but we cannot give a precise date when this will happen. We hope that by the end of this year,” said the director of the Butantan Institute, Dimas Covas, during a press conference at the Palácio dos Bandeirantes this afternoon .
Previously, Governor Doria had said that Coronavac, a coronavirus vaccine that will be produced by the Butantan Institute in partnership with the Chinese laboratory Sinovac, could begin to be applied to health professionals from December 15, if approved. in all. the exams.
After the interview, questioned by the report of the Twitter if it is possible to say that the vaccine will start on December 15 as previously announced, Covas replied, “No, I don’t think so.”
Experts have said that almost no vaccine is ready for use this year. The WHO itself (World Health Organization) declared that Brazil will not have a mass vaccination against the new coronavirus even next year. The organization believes that the world’s population will have to wait until 2022.
Behind the scenes, the race for a vaccine is seen as a feud between Doria and President Jair Bolsonaro (no party) with his sights set on the 2022 elections.
The butantan vaccine is the most advanced, says Doria
At today’s press conference, Doria also said that the Butantan vaccine is the most advanced among all those produced in the world.
“The first results of the clinical study show that, among all vaccines, Coronavac is the safest and the one with the best and most promising rates. It is, in fact, the most advanced vaccine at this time,” he said.
The state government released the results of Coronavac tests with 9,000 volunteers in the country today. According to Covas, the vaccine had few side effects and the results in Brazil show that the vaccine is safe.
According to the results presented, 35% of the volunteers had some type of side effect after the application of the vaccine, being pain at the application site the most common, reported by 18% of those who received the dose.
Grade 3 reactions, which are more serious, have not been reported. Only 0.1% of the volunteers had a fever.
“The other reactions were statistically insignificant. The most common was headache, which may or may not be related to a vaccine. The other symptoms were very low,” Covas said. “So it is the safest vaccine not only in Brazil, but in the world.”
